SCHEMBL24744906

SCHEMBL24744906

Cc1nc2c(C(=O)O)cc(Br)cc2n1CC(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
DHODH Q02127 1/20 0.37
PIK3C2B O00750 7/20 0.36
HSD17B10 Q99714 1/20 0.35
PIK3CD O00329 1/20 0.35
PIK3R1 P27986 1/20 0.35
PIK3CB P42338 1/20 0.35
CACNA1B Q00975 1/20 0.34
AKR1B10 O60218 1/20 0.33
PTGER4 P35408 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
HTT P42858 1/20 0.32
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24744896 0.89 KDM4E (0.36) KDM4EALDH1A1CACNA1BPTGER4POLB
SCHEMBL24745714 0.88 DHODH (0.48) KDM4EALDH1A1DHODHPIK3C2BPIK3CD
SCHEMBL31090614 0.88 DHODH (0.48) KDM4EALDH1A1DHODHPIK3C2BPIK3CD
SCHEMBL24745459 0.86 ALDH1A1 (0.37) KDM4EALDH1A1DHODHPIK3C2BHSD17B10
SCHEMBL31090610 0.86 PIK3C2B (0.40) KDM4EALDH1A1DHODHPIK3C2BPIK3CD
SCHEMBL24745592 0.86 PIK3C2B (0.40) KDM4EALDH1A1DHODHPIK3C2BPIK3CD
SCHEMBL24745416 0.85 ALDH1A1 (0.39) KDM4EALDH1A1DHODHPIK3C2BHSD17B10
SCHEMBL24744761 0.81 KDM4E (0.46) KDM4EALDH1A1DHODHPIK3C2BHSD17B10
SCHEMBL30952847 0.81 KDM4E (0.46) KDM4EALDH1A1DHODHPIK3C2BHSD17B10
SCHEMBL24744879 0.78 KDM4E (0.38) KDM4EALDH1A1CACNA1BAKR1B10PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2024-09-05 US disclosed
CN-117957218-A Targeted protein degradation using bifunctional compounds that bind to ubiquitin ligases and target MCL-1 proteins 凯普托尔治疗学股份有限公司 2024-04-30 CN disclosed
WO-2022253713-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN CAPTOR THERAPEUTICS S.A. (PL) 2022-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294499-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN MCL1, MDM2, XIAP KDM4E 1943/4885ALDH1A1 956/4885DHODH 2722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.